Preliminary results of the first vaccine to enter the human trial to prevent the outbreak of the novel corona virus have been impressive.
The US company Moderina launched the first experimental vaccine for corona virus, MRNA 1273, on humans in March, and now, about four months later, the full results of the first phase have been released. The results were released.
The findings, published in the medical journal The New England Journal of Medicine, show that the experimental vaccine is safe for humans and has the potential to produce the immune response needed to protect against the corona virus.
Experts from the US National Institutes of Health Sciences, which is involved in developing the vaccine, said the findings reinforce the idea of further research on the vaccine.
The findings come as Moderina launches the third and final phase of the vaccine on July 27, involving 30,000 people to see how effective the vaccine is in preventing the corona virus.
The results, released Tuesday night, noted the effects of the vaccine on 45 volunteers who took part in an initial vaccine trial in March.
These volunteers, aged 18 to 55, were divided into 3 groups and given low, medium or high doses.
In the blood of these volunteers, antibodies to the virus were developed to the same level as those found in those who defeated Code 19.
During the trial, some volunteers were given 2 doses of the vaccine in a few weeks, which helped increase antibody levels.
The results of the study were encouraging, but their main purpose was to see if the vaccine could help improve the immune response to humans.
Nowhere in this study is it clear whether the vaccine can actually protect people from the virus, while it is not yet known how much immune response people need to protect or how long it will last. Will be safe
The answers to these questions will be revealed in a final trial of 30,000 people, in which one group will be given a vaccine and the other a placebo (a harmless substance given as medicine).
The two groups will then be compared to see who is most affected by Code 19.
In the initial study, the majority of volunteers reported various side effects that were minor.
The most common side effects were fatigue, chills, headaches, muscle aches and pain at the injection site.
3 out of 15 people with high doses reported one or more severe side effects.
Some of the side effects were similar to those of the corona virus, but they did not last more than a day after vaccination.
According to medical experts, protection against code 19 has to pay a small price and preliminary results are the first positive step. It is expected that the final trial will finally decide how safe and effective the vaccine is and how long it will be available. Will be.
The company recently completed the second phase of the vaccine, which included young and old, but the results have not yet been released.
It is believed that more than 150 corona vaccines are currently being developed worldwide, with 21 undergoing human testing.
Along with Moderina, vaccines from Oxford University in China and the United Kingdom have also entered the final stages of human testing.
After the third phase of the Moderina vaccine, the FDA will decide whether to approve the use of the vaccine, which will only be approved if it proves to be safe and effective while its benefits outweigh the risks.
The statement said that more people would be able to get protection from the virus.
It is thought that it usually takes several years to develop a vaccine, but due to the rapid spread of the corona virus, vaccine production is also accelerating.
But it is not only a challenge to make the vaccine effective and safe, but also to provide billions of doses.
Several companies, including Modrina, have announced that they will begin mass production of the vaccine before all clinical trials are completed.
Moderina has announced a partnership with Lonza, a major pharmaceutical company, for this purpose, with the potential to produce one billion doses a year.
It should be noted that this vaccine uses a new technology that has not been used in any other approved vaccine so far.
Most traditional vaccines use a weakened or weakened version of the virus to train the body’s immune system to fight it, but this new vaccine uses a molecular messenger RNA that allows cells to make viral proteins on their own. Directs
MRNA directs cells to make spike proteins from the corona virus, which the virus uses to infect human cells.
The idea is that it will help the immune system identify spike proteins and make antibodies against them.
This technology is being described as a faster method of vaccine development and more stable than conventional vaccines.